PhenylketonuriasNCT04969809
Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients
A study testing Ultrasound of the jugular veins and addition of phenylalanine-free protein substitutes in people with Phenylketonurias and Nutritional and Metabolic Diseases, run by University Medical Centre Ljubljana.
Trial summary
Phenylketonuria is a rare metabolic disease that results from the absence or near-absence activity of the enzyme phenylalanine hydroxylase, which metabolizes the amino acid phenylalanine to tyrosine in the body. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Phenylketonurias, Nutritional and Metabolic Diseases
- What is being tested?
- Ultrasound of the jugular veins and addition of phenylalanine-free protein substitutes
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2021to 1 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The study will include subjects over the age of 18 who have PKU or hyperphenylalaninemia and are expected to have dietary treatment according to expert recommendations. A prerequisite for entering the investigation will be a signed consent to participate in the investigation and the ability of the participant to have a good understanding of the content of the research and to fully participate in the interventional dietary process.
Who cannot join
- The investigators will not include adult patients who do not manage their diet on their own and need caregivers due to limited cognitive abilities (patients with late-diagnosed disease and neurological consequences of the disease) or who do not want to sign an informed consent.
Trial locations and contacts
No sites are listed yet.
Mojca Žerjav Tanšek, doctorate contact
About this study
Phenylketonuria is a rare metabolic disease that results from the absence or near-absence activity of the enzyme phenylalanine hydroxylase, which metabolizes the amino acid phenylalanine to tyrosine in the body. Accumulation of phenylalanine in the brain causes brain damage that leads to mental retardation, neurological complications, and movement disorders.
The study is inherited autosomal recessively. The basis of treatment is a low-protein diet with dietary supplements of aminoxlin without phenylalanine and with appropriate substitutes for micro and macronutrients needed for different ages. A low-protein diet regulates the level of phenylalanine in the blood. This is especially important in childhood.
Read more
In the study, which will basically consist of theoretical, experimental and numerical work, the investigators will limit to a specific population, i.e. to adult patients with phenylketonuria. The research is intended to prove the hypothesis that with proper nutritional treatment of phenylketonuria in adulthood, we can have a positive effect on the patient's well-being, better blood results and improved lifestyle.
The investigators intend to test this hypothesis by implementing a complex, multidisciplinary project that will include a comprehensive treatment of adult PKU patients. This will be based on a multidisciplinary approach with the inclusion of medical and nutritional treatment. As part of the project, the investigators, among other things, create questionnaires and analyze food diaries related to the mentioned areas.
Using various statistical techniques, the investigators analyze the impact of individual factors on the success of achieving the objectives of the proposed study. The original contribution to science will be the nutritional treatment of adult patients with phenylketonuria in Slovenia and the consequent reduction of health complications in adulthood of patients with phenylketonuria.
Read the detailed description
Selection and presentation of the problem and formulation of goals Phenylketonuria (PKU) oz. Hyperphenylalaninemia (HPA) is a rare congenital metabolic disease (PPB) due to a lack of phenylalanine hydroxylase (PH) activity, which metabolizes the amino acid phenylalanine (Phe) to tyrosine in the body. The cause is a disease change in the PAH gene that encodes the enzyme PH. A baby is born healthy, but elevated Phe levels without proper treatment cause central nervous system damage and permanent mental retardation in the first months after birth. The disease is the first PPB to be detected by medicine with neonatal screening tests and also successfully treated with dietary treatment that excludes foods with a higher Phe content from the diet. In Slovenia, the screening test was introduced in 1979 and with a calculated incidence of PKU 1/6769 in Slovenia (Šmon et al., 2015), there are approximately 150 patients with PKU in the Slovenian registry, of which more than half are over 18 years of age.
Nutritional treatment is an important part of PKU treatment and should be performed for life according to modern guidelines (Cazzorla et al., 2018).
Dietary treatment of PKU is one of the strictest diets, where almost all foods containing protein are excluded from the food, ie all diets of animal origin (meat, milk and all dairy products, eggs) as well as all cereals, legumes and nuts. Patients consume only limited amounts of fruits and vegetables and special products with a removed protein content. They compensate for the protein deficiency with special Phe-free protein substitutes. Adult patients with PKU often do not reach the recommended levels of Phe in the blood (Green et al., 2019), as the consequences of abandoning the diet in adulthood are not as obvious and disturbing. By abandoning the diet, however, they also abandon follow-up in a specialist PPB clinic, and according to studies, more than 70% of adult patients with PKU (study in America) are no longer managed in metabolic clinics (Berry et al., 2013).
Successful disease management often requires a lifelong diet that provides an appropriately limited daily intake of Phe for growth and body regeneration with a small portion of essential amino acids, vitamins, and natural food elements, and the remaining missing portion of these dietary sources is added in the form of protein-fortified protein. , which does not contain the amino acid Phe (MacLeod et al., 2009). Phe tolerance (mg Phe / kg body weight / day) is the amount of Phe that PKU patients can consume daily while maintaining recommended blood Phe levels. An individual assessment is required due to the very diverse level of Phe hydroxylase enzyme activity still present (MacLeod et al., 2009). The measure of dietary success is an adequate value of serum Phe and the latest European recommendations in adulthood are between 120 - 600 μmol / L (van Spronsen et al., 2017; van Wegberg et al., 2017).
Research in recent years has shown significantly higher morbidity and health risk in adult patients with PKU. Part of the health problems are also more present in patients who continue dietary treatment, and there are even more problems in untreated patients (Burton et al., 2018).
Increased health risks have already been described, including the following medical conditions:
- Increased cardiovascular risk and increased atherogenic indicators (Azabdaftari et al., 2019)
- Higher body mass index (Robertson et al., 2013)
- The impact of disease and diet on bone density (Hansen et al., 2014)
- Nutritional deficits (Okano et al., 2016, Moseley et al., 2002)
- Higher proportion of brain dysfunction (Hoedt et al., 2012)
- Gastrointestinal dysbiosis (Verduci et al., 2020)
- Increased general comorbidity (Burton et al., 2018)
All these increased risks mean that this group of patients needs regular medical monitoring even in adulthood. It is known that a proportion of patients relax their diet and thus their Phe intake, but maintain a self-limiting diet with a low protein intake while not consuming a protein substitute (Das et al., 2014). Adequate daily protein intake is important as it ensures proper body protein synthesis and prevents catabolism (MacLeod et al., 2009).
The purpose of the research
Primary goal:
- Use a questionnaire in patients to assess the differences between the group of patients on dietary treatment and the group of patients who discontinued treatment: demographic characteristics (gender, age, education, source of income, marital status), comorbidities or treatments, smoking , sleep disorders, self - assessment of physical activity, self - assessment of health.
- To determine the effectiveness of the dietary intervention of individual nutrition counseling for reduced Phe intake in the blood and the balance of nutrients and elements in the diet by assessing the following indicators, before and after 6 months of intervention:
- quantitative reduction of Phe consumption in the diet and adequacy of Phe amino acid preparation with the addition of vitamins and elements, which will be assessed by measurements in the blood: Phe, amino acids, vitamins, trace elements, methylmalonic acid in urine
- Compliance assessment with analysis of food diaries (at the first examination and after 6 months)
Secondary objectives are:
- Comparison of assessment of risk factors for atherogenesis between patients considering dietary treatment and among patients without dietary treatment with ultrasound of the jugular veins to assess the thickness of the carotid intima media and assessment of oxidative stress in the urine sample and body composition at the start of the study
- Assessment of risk factors for atherogenesis before and after dietary intervention
- Determine the change in body mass index, waist circumference before and after the intervention, blood pressure
- Identify the change of selected laboratory atherogenic biomarkers (total lipidogram, Lp (a), homocysteine, CRP low, Il-6, TNF alpha, blood sugar, insulin) Presentation of methods
The investigators will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment, while half have abandoned the treatment and mostly no longer come for outpatient examinations.
The research will be conducted prospectively. Institution where the research will be conducted: Clinical Department of Endocrinology, Diabetes and Metabolic Diseases, Pediatric Clinic, University Medical Center Ljubljana, Bohoričeva 20, 1000 Ljubljana
Nutritional analyzes and interventional dietary counseling will be performed simultaneously with the regular medical control outpatient examination before the nutritional intervention and the analysis will be repeated after 6 months.
INTRODUCTORY REVIEW:
Ultrasound of the jugular veins to assess the thickness of the carotid intima media as a non-invasive biomarker of atherosclerosis (cIMT) will be performed by a specialist as a regular existing examination method during outpatient examination of the patient (non-invasive ultrasound probe MyLab Gamma with QIMT® software according to the manufacturer's instructions).
The first inspection will also include:
- Completion of a questionnaire (Physical Activity Questionnaire (International Physical Activity Questionnaire), Sleep Questionnaire (Insomnia Severity Questionnaire (ISI)),
- performing anthropometric measurements (body weight (kg), body height (cm), waist circumference (cm)) (validated scales, stadiometer, prescribed waist circumference measurement procedure)
- measurement of systolic and diastolic blood pressure (mmHg) and resting pulse,
- nutrition analysis (by completing nutrition diaries and / or an interview at the examination)
- taking a blood sample
- taking a urine sample
- body composition measurement - BIA
- OGTT testing
Nutrition analysis and interventional nutrition counseling will include:
Definition of diet To define the diet (energy and nutrient intake), the investigators use the diet diary (PD) of the patient's diet for three days (3 x 24 hours (I .: 0 months = before the 1st examination; PD 0)) and 3 x 24 hours, where patients food diary will be carefully reviewed by a dietitian and will be entered into the Prodi® program for further processing and calculation of detailed energy and nutrient intake. preparation of menus, composition of individual recipes and calculation of nutrient and energy intake.
Subjects will receive one hour of nutritional counseling in a diet counseling center by a clinical dietitian.
Nutritional counseling will be based on the nutritional assessment of the patient's condition and the direction of improvement - the development of a diet plan. The dietitian will make a motivational phone call each month. Written instructions will be given to the examinees.
REVIEW AFTER 6 MONTHS:
The inspection will include:
- filling in the sleep disorder questionnaire, self-assessment of physical activity, self-assessment of health
- performing anthropometric measurements (body weight (kg), body height (cm), waist circumference (cm)) (use of a validated balance, stadiometer, prescribed waist circumference measurement procedure)
- measurement of systolic and diastolic blood pressure (mmHg),
- nutrition analysis (by completing nutrition diaries and screening interviews)
- taking a blood sample
- taking a urine sample
- body measurement
- Being tested
- Ultrasound of the jugular veins, addition of phenylalanine-free protein substitutes
- Keywords
- adult phenylketonuria, nutrition therapy, cardiovascular diseases, nutrition and metabolic diseases
- Medical subject headings
- Phenylketonurias, Nutritional and Metabolic Diseases, Cardiovascular Diseases, Metabolic Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ultrasound of the jugular veinsDiagnostic test
Ultrasound of the jugular veins to assess the thickness of the carotid intima media
addition of phenylalanine-free protein substitutesDietary supplement
addition of phenylalanine-free protein substitutes for sufficient daily intake of essential amino acids and other vitamins and minerals and nutritional plan
| Study group | Role | What they receive |
|---|---|---|
| Patients on diet | Experimental | We will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment. Receives: Diagnostic Test: Ultrasound of the jugular veins; Dietary Supplement: addition of phenylalanine-free protein substitutes |
| patients without diet | Experimental | Half of the patients have abandoned the diet treatment and mostly no longer come for outpatient examinations. Receives: Diagnostic Test: Ultrasound of the jugular veins; Dietary Supplement: addition of phenylalanine-free protein substitutes |
What is being measured
The primary outcome is the main question the study is designed to answer.
assess the differences between the group of patients with questionnaire
Use a questionnaire in patients to assess the differences between the group of patients on dietary treatment and the group of patients who discontinued treatment: demographic characteristics (gender, age, education, source of income, marital status), comorbidities or treatments, smoking , sleep disorders, self - assessment of physical activity, self - assessment of health.
Measured: up to 6 months
Determination of the effectiveness of the dietary intervention of individual nutrition counseling for reduced Phe intake in the blood and the balance of nutrients and elements in the diet
Phe intake in the blood (µmol/L)
Measured: up to 6 months
Secondary outcomes (5)
Comparison of the assessment of risk factors for atherogenesis
ultrasound of the jugular veins to assess the thickness of the carotid intima media (percent)
Measured: 1 day
Assessment of risk factors for atherogenesis before and after dietary intervention 1
Determine the change in body mass index (kg/m²)
Measured: up to 6 months
Assessment of risk factors for atherogenesis before and after dietary intervention 2
waist circumference (cm)
Measured: up to 6 months
Assessment of risk factors for atherogenesis before and after dietary intervention 3
blood pressure (mm Hg)
Measured: up to 6 months
Bioelectrical impedance analysis (BIA)
Body fat measurements (%)
Measured: up to 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jul 2021
- Study start1 Sep 2021 (estimated)
- Primary completion1 Sep 2026 (estimated)
- Study completion1 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (21)Papers the sponsor has linked to this study.
- Other trials for PhenylketonuriasStudies of the same condition, open and under way.
- More trials run by University Medical Centre LjubljanaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- We will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment, while half have abandoned the treatment and mostly no longer come for outpatient examinations.
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Medical Centre Ljubljana
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ajda Mezek, University Medical Centre Ljubljana
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04969809
- Sponsor's protocol ID
- AMezek
- Status last verified
- Jul 2021
- First submitted
- 21 Jun 2021
- Last updated
- 21 Jul 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Azabdaftari A, van der Giet M, Schuchardt M, Hennermann JB, Plockinger U, Querfeld U. The cardiovascular phenotype of adult patients with phenylketonuria. Orphanet J Rare Dis. 2019 Sep 6;14(1):213. doi: 10.1186/s13023-019-1188-0.
PubMed 31492166Berry SA, Brown C, Grant M, Greene CL, Jurecki E, Koch J, Moseley K, Suter R, van Calcar SC, Wiles J, Cederbaum S. Newborn screening 50 years later: access issues faced by adults with PKU. Genet Med. 2013 Aug;15(8):591-9. doi: 10.1038/gim.2013.10. Epub 2013 Mar 7.
PubMed 23470838Burton BK, Jones KB, Cederbaum S, Rohr F, Waisbren S, Irwin DE, Kim G, Lilienstein J, Alvarez I, Jurecki E, Levy H. Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria. Mol Genet Metab. 2018 Nov;125(3):228-234. doi: 10.1016/j.ymgme.2018.09.006. Epub 2018 Sep 12.
PubMed 30266197Cazzorla C, Bensi G, Biasucci G, Leuzzi V, Manti F, Musumeci A, Papadia F, Stoppioni V, Tummolo A, Vendemiale M, Polo G, Burlina A. Living with phenylketonuria in adulthood: The PKU ATTITUDE study. Mol Genet Metab Rep. 2018 Jul 11;16:39-45. doi: 10.1016/j.ymgmr.2018.06.007. eCollection 2018 Sep.
PubMed 30069431Das AM, Goedecke K, Meyer U, Kanzelmeyer N, Koch S, Illsinger S, Lucke T, Hartmann H, Lange K, Lanfermann H, Hoy L, Ding XQ. Dietary habits and metabolic control in adolescents and young adults with phenylketonuria: self-imposed protein restriction may be harmful. JIMD Rep. 2014;13:149-58. doi: 10.1007/8904_2013_273. Epub 2013 Nov 13.
PubMed 24222493Ford S, O'Driscoll M, MacDonald A. Living with Phenylketonuria: Lessons from the PKU community. Mol Genet Metab Rep. 2018 Oct 18;17:57-63. doi: 10.1016/j.ymgmr.2018.10.002. eCollection 2018 Dec.
PubMed 30364670Green B, Browne R, Firman S, Hill M, Rahman Y, Kaalund Hansen K, Adam S, Skeath R, Hallam P, Herlihy I, Jenkinson F, Nicol C, Adams S, Gaff L, Donald S, Dawson C, Robertson L, Fitzachary C, Chan H, Slabbert A, Dunlop C, Cozens A, Newby C, Bittle V, Hubbard G, Stratton R. Nutritional and Metabolic Characteristics of UK Adult Phenylketonuria Patients with Varying Dietary Adherence. Nutrients. 2019 Oct 14;11(10):2459. doi: 10.3390/nu11102459.
PubMed 31615158Hansen KE, Ney D. A systematic review of bone mineral density and fractures in phenylketonuria. J Inherit Metab Dis. 2014 Nov;37(6):875-80. doi: 10.1007/s10545-014-9735-2. Epub 2014 Jul 9.
PubMed 25005329Hermida-Ameijeiras A, Crujeiras V, Roca I, Calvo C, Leis R, Couce ML. Arterial stiffness assessment in patients with phenylketonuria. Medicine (Baltimore). 2017 Dec;96(51):e9322. doi: 10.1097/MD.0000000000009322.
PubMed 29390507MacDonald A, Gokmen-Ozel H, van Rijn M, Burgard P. The reality of dietary compliance in the management of phenylketonuria. J Inherit Metab Dis. 2010 Dec;33(6):665-70. doi: 10.1007/s10545-010-9073-y. Epub 2010 Apr 7.
PubMed 20373144MacLeod EL, Gleason ST, van Calcar SC, Ney DM. Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes. Mol Genet Metab. 2009 Dec;98(4):331-7. doi: 10.1016/j.ymgme.2009.07.016. Epub 2009 Aug 8.
PubMed 19747868Okano Y, Hattori T, Fujimoto H, Noi K, Okamoto M, Watanabe T, Watanabe R, Fujii R, Tamaoki T. Nutritional status of patients with phenylketonuria in Japan. Mol Genet Metab Rep. 2016 Aug 20;8:103-10. doi: 10.1016/j.ymgmr.2016.08.005. eCollection 2016 Sep.
PubMed 27595068Robertson LV, McStravick N, Ripley S, Weetch E, Donald S, Adam S, Micciche A, Boocock S, MacDonald A. Body mass index in adult patients with diet-treated phenylketonuria. J Hum Nutr Diet. 2013 Jul;26 Suppl 1:1-6. doi: 10.1111/jhn.12054. Epub 2013 Apr 3.
PubMed 23551621Rocha JC, MacDonald A. Dietary intervention in the management of phenylketonuria: current perspectives. Pediatric Health Med Ther. 2016 Dec 1;7:155-163. doi: 10.2147/PHMT.S49329. eCollection 2016.
PubMed 29388626Rocha JC, MacDonald A, Trefz F. Is overweight an issue in phenylketonuria? Mol Genet Metab. 2013;110 Suppl:S18-24. doi: 10.1016/j.ymgme.2013.08.012. Epub 2013 Aug 31.
PubMed 24055312
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Atherogenic Risk Factors and Efficacy of Nutritional Treatment Among Adult Phenylketonuria Patients
- ClinicalTrials.gov ID
- NCT04969809
- Acronym / sponsor ID
- AMezek
- Keywords
- adult phenylketonuria, nutrition therapy, cardiovascular diseases, nutrition and metabolic diseases
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University Medical Centre LjubljanaUniversity, hospital or other
- Study start
- 1 Sep 2021 (estimated)
- Primary completion
- 1 Sep 2026 (estimated)
- Study completion
- 1 Sep 2026 (estimated)
- First posted
- 21 Jul 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Phenylketonuria is a rare metabolic disease that results from the absence or near-absence activity of the enzyme phenylalanine hydroxylase, which metabolizes the amino acid phenylalanine to tyrosine in the body. Accumulation of phenylalanine in the brain causes brain damage that leads to mental retardation, neurological complications, and movement disorders.
The study is inherited autosomal recessively. The basis of treatment is a low-protein diet with dietary supplements of aminoxlin without phenylalanine and with appropriate substitutes for micro and macronutrients needed for different ages. A low-protein diet regulates the level of phenylalanine in the blood. This is especially important in childhood.
In the study, which will basically consist of theoretical, experimental and numerical work, the investigators will limit to a specific population, i.e. to adult patients with phenylketonuria. The research is intended to prove the hypothesis that with proper nutritional treatment of phenylketonuria in adulthood, we can have a positive effect on the patient's well-being, better blood results and improved lifestyle.
The investigators intend to test this hypothesis by implementing a complex, multidisciplinary project that will include a comprehensive treatment of adult PKU patients. This will be based on a multidisciplinary approach with the inclusion of medical and nutritional treatment. As part of the project, the investigators, among other things, create questionnaires and analyze food diaries related to the mentioned areas.
Using various statistical techniques, the investigators analyze the impact of individual factors on the success of achieving the objectives of the proposed study. The original contribution to science will be the nutritional treatment of adult patients with phenylketonuria in Slovenia and the consequent reduction of health complications in adulthood of patients with phenylketonuria.
Detailed description
Selection and presentation of the problem and formulation of goals Phenylketonuria (PKU) oz. Hyperphenylalaninemia (HPA) is a rare congenital metabolic disease (PPB) due to a lack of phenylalanine hydroxylase (PH) activity, which metabolizes the amino acid phenylalanine (Phe) to tyrosine in the body. The cause is a disease change in the PAH gene that encodes the enzyme PH. A baby is born healthy, but elevated Phe levels without proper treatment cause central nervous system damage and permanent mental retardation in the first months after birth. The disease is the first PPB to be detected by medicine with neonatal screening tests and also successfully treated with dietary treatment that excludes foods with a higher Phe content from the diet. In Slovenia, the screening test was introduced in 1979 and with a calculated incidence of PKU 1/6769 in Slovenia (Šmon et al., 2015), there are approximately 150 patients with PKU in the Slovenian registry, of which more than half are over 18 years of age.
Nutritional treatment is an important part of PKU treatment and should be performed for life according to modern guidelines (Cazzorla et al., 2018).
Dietary treatment of PKU is one of the strictest diets, where almost all foods containing protein are excluded from the food, ie all diets of animal origin (meat, milk and all dairy products, eggs) as well as all cereals, legumes and nuts. Patients consume only limited amounts of fruits and vegetables and special products with a removed protein content. They compensate for the protein deficiency with special Phe-free protein substitutes. Adult patients with PKU often do not reach the recommended levels of Phe in the blood (Green et al., 2019), as the consequences of abandoning the diet in adulthood are not as obvious and disturbing. By abandoning the diet, however, they also abandon follow-up in a specialist PPB clinic, and according to studies, more than 70% of adult patients with PKU (study in America) are no longer managed in metabolic clinics (Berry et al., 2013).
Successful disease management often requires a lifelong diet that provides an appropriately limited daily intake of Phe for growth and body regeneration with a small portion of essential amino acids, vitamins, and natural food elements, and the remaining missing portion of these dietary sources is added in the form of protein-fortified protein. , which does not contain the amino acid Phe (MacLeod et al., 2009). Phe tolerance (mg Phe / kg body weight / day) is the amount of Phe that PKU patients can consume daily while maintaining recommended blood Phe levels. An individual assessment is required due to the very diverse level of Phe hydroxylase enzyme activity still present (MacLeod et al., 2009). The measure of dietary success is an adequate value of serum Phe and the latest European recommendations in adulthood are between 120 - 600 μmol / L (van Spronsen et al., 2017; van Wegberg et al., 2017).
Research in recent years has shown significantly higher morbidity and health risk in adult patients with PKU. Part of the health problems are also more present in patients who continue dietary treatment, and there are even more problems in untreated patients (Burton et al., 2018).
Increased health risks have already been described, including the following medical conditions:
- Increased cardiovascular risk and increased atherogenic indicators (Azabdaftari et al., 2019)
- Higher body mass index (Robertson et al., 2013)
- The impact of disease and diet on bone density (Hansen et al., 2014)
- Nutritional deficits (Okano et al., 2016, Moseley et al., 2002)
- Higher proportion of brain dysfunction (Hoedt et al., 2012)
- Gastrointestinal dysbiosis (Verduci et al., 2020)
- Increased general comorbidity (Burton et al., 2018)
All these increased risks mean that this group of patients needs regular medical monitoring even in adulthood. It is known that a proportion of patients relax their diet and thus their Phe intake, but maintain a self-limiting diet with a low protein intake while not consuming a protein substitute (Das et al., 2014). Adequate daily protein intake is important as it ensures proper body protein synthesis and prevents catabolism (MacLeod et al., 2009).
The purpose of the research
Primary goal:
- Use a questionnaire in patients to assess the differences between the group of patients on dietary treatment and the group of patients who discontinued treatment: demographic characteristics (gender, age, education, source of income, marital status), comorbidities or treatments, smoking , sleep disorders, self - assessment of physical activity, self - assessment of health.
- To determine the effectiveness of the dietary intervention of individual nutrition counseling for reduced Phe intake in the blood and the balance of nutrients and elements in the diet by assessing the following indicators, before and after 6 months of intervention:
- quantitative reduction of Phe consumption in the diet and adequacy of Phe amino acid preparation with the addition of vitamins and elements, which will be assessed by measurements in the blood: Phe, amino acids, vitamins, trace elements, methylmalonic acid in urine
- Compliance assessment with analysis of food diaries (at the first examination and after 6 months)
Secondary objectives are:
- Comparison of assessment of risk factors for atherogenesis between patients considering dietary treatment and among patients without dietary treatment with ultrasound of the jugular veins to assess the thickness of the carotid intima media and assessment of oxidative stress in the urine sample and body composition at the start of the study
- Assessment of risk factors for atherogenesis before and after dietary intervention
- Determine the change in body mass index, waist circumference before and after the intervention, blood pressure
- Identify the change of selected laboratory atherogenic biomarkers (total lipidogram, Lp (a), homocysteine, CRP low, Il-6, TNF alpha, blood sugar, insulin) Presentation of methods
The investigators will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment, while half have abandoned the treatment and mostly no longer come for outpatient examinations.
The research will be conducted prospectively. Institution where the research will be conducted: Clinical Department of Endocrinology, Diabetes and Metabolic Diseases, Pediatric Clinic, University Medical Center Ljubljana, Bohoričeva 20, 1000 Ljubljana
Nutritional analyzes and interventional dietary counseling will be performed simultaneously with the regular medical control outpatient examination before the nutritional intervention and the analysis will be repeated after 6 months.
INTRODUCTORY REVIEW:
Ultrasound of the jugular veins to assess the thickness of the carotid intima media as a non-invasive biomarker of atherosclerosis (cIMT) will be performed by a specialist as a regular existing examination method during outpatient examination of the patient (non-invasive ultrasound probe MyLab Gamma with QIMT® software according to the manufacturer's instructions).
The first inspection will also include:
- Completion of a questionnaire (Physical Activity Questionnaire (International Physical Activity Questionnaire), Sleep Questionnaire (Insomnia Severity Questionnaire (ISI)),
- performing anthropometric measurements (body weight (kg), body height (cm), waist circumference (cm)) (validated scales, stadiometer, prescribed waist circumference measurement procedure)
- measurement of systolic and diastolic blood pressure (mmHg) and resting pulse,
- nutrition analysis (by completing nutrition diaries and / or an interview at the examination)
- taking a blood sample
- taking a urine sample
- body composition measurement - BIA
- OGTT testing
Nutrition analysis and interventional nutrition counseling will include:
Definition of diet To define the diet (energy and nutrient intake), the investigators use the diet diary (PD) of the patient's diet for three days (3 x 24 hours (I .: 0 months = before the 1st examination; PD 0)) and 3 x 24 hours, where patients food diary will be carefully reviewed by a dietitian and will be entered into the Prodi® program for further processing and calculation of detailed energy and nutrient intake. preparation of menus, composition of individual recipes and calculation of nutrient and energy intake.
Subjects will receive one hour of nutritional counseling in a diet counseling center by a clinical dietitian.
Nutritional counseling will be based on the nutritional assessment of the patient's condition and the direction of improvement - the development of a diet plan. The dietitian will make a motivational phone call each month. Written instructions will be given to the examinees.
REVIEW AFTER 6 MONTHS:
The inspection will include:
- filling in the sleep disorder questionnaire, self-assessment of physical activity, self-assessment of health
- performing anthropometric measurements (body weight (kg), body height (cm), waist circumference (cm)) (use of a validated balance, stadiometer, prescribed waist circumference measurement procedure)
- measurement of systolic and diastolic blood pressure (mmHg),
- nutrition analysis (by completing nutrition diaries and screening interviews)
- taking a blood sample
- taking a urine sample
- body measurement
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
- Model description
- We will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment, while half have abandoned the treatment and mostly no longer come for outpatient examinations.
| Arm | Type | Receives |
|---|---|---|
| Patients on diet | Experimental | Diagnostic Test: Ultrasound of the jugular veins, Dietary Supplement: addition of phenylalanine-free protein substitutesWe will invite approximately 50 adult patients with PKU who were or are still being managed in the PPB clinic of the Pediatric Clinic of the University Medical Center Ljubljana. It is estimated that half of the patients still fully or at least partially follow the dietary treatment. |
| patients without diet | Experimental | Diagnostic Test: Ultrasound of the jugular veins, Dietary Supplement: addition of phenylalanine-free protein substitutesHalf of the patients have abandoned the diet treatment and mostly no longer come for outpatient examinations. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- The study will include subjects over the age of 18 who have PKU or hyperphenylalaninemia and are expected to have dietary treatment according to expert recommendations. A prerequisite for entering the investigation will be a signed consent to participate in the investigation and the ability of the participant to have a good understanding of the content of the research and to fully participate in the interventional dietary process.
Key exclusion criteria (1 listed)
- The investigators will not include adult patients who do not manage their diet on their own and need caregivers due to limited cognitive abilities (patients with late-diagnosed disease and neurological consequences of the disease) or who do not want to sign an informed consent.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ultrasound of the jugular veinsUltrasound of the jugular veins to assess the thickness of the carotid intima media | Diagnostic test | Patients on diet, patients without diet |
| addition of phenylalanine-free protein substitutesaddition of phenylalanine-free protein substitutes for sufficient daily intake of essential amino acids and other vitamins and minerals and nutritional plan | Dietary supplement | Patients on diet, patients without diet |
Primary outcome
assess the differences between the group of patients with questionnaire
Time frame: up to 6 months
Use a questionnaire in patients to assess the differences between the group of patients on dietary treatment and the group of patients who discontinued treatment: demographic characteristics (gender, age, education, source of income, marital status), comorbidities or treatments, smoking , sleep disorders, self - assessment of physical activity, self - assessment of health.
Determination of the effectiveness of the dietary intervention of individual nutrition counseling for reduced Phe intake in the blood and the balance of nutrients and elements in the diet
Time frame: up to 6 months
Phe intake in the blood (µmol/L)
5 secondary outcomes
Comparison of the assessment of risk factors for atherogenesis
Time frame: 1 day
Assessment of risk factors for atherogenesis before and after dietary intervention 1
Time frame: up to 6 months
Assessment of risk factors for atherogenesis before and after dietary intervention 2
Time frame: up to 6 months
Assessment of risk factors for atherogenesis before and after dietary intervention 3
Time frame: up to 6 months
Bioelectrical impedance analysis (BIA)
Time frame: up to 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2021.
- Background: PubMed 31492166Azabdaftari A, van der Giet M, Schuchardt M, Hennermann JB, Plockinger U, Querfeld U. The cardiovascular phenotype of adult patients with phenylketonuria. Orphanet J Rare Dis. 2019 Sep 6;14(1):213. doi: 10.1186/s13023-019-1188-0.
- Background: PubMed 23470838Berry SA, Brown C, Grant M, Greene CL, Jurecki E, Koch J, Moseley K, Suter R, van Calcar SC, Wiles J, Cederbaum S. Newborn screening 50 years later: access issues faced by adults with PKU. Genet Med. 2013 Aug;15(8):591-9. doi: 10.1038/gim.2013.10. Epub 2013 Mar 7.
- Background: PubMed 30266197Burton BK, Jones KB, Cederbaum S, Rohr F, Waisbren S, Irwin DE, Kim G, Lilienstein J, Alvarez I, Jurecki E, Levy H. Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria. Mol Genet Metab. 2018 Nov;125(3):228-234. doi: 10.1016/j.ymgme.2018.09.006. Epub 2018 Sep 12.
- Background: PubMed 30069431Cazzorla C, Bensi G, Biasucci G, Leuzzi V, Manti F, Musumeci A, Papadia F, Stoppioni V, Tummolo A, Vendemiale M, Polo G, Burlina A. Living with phenylketonuria in adulthood: The PKU ATTITUDE study. Mol Genet Metab Rep. 2018 Jul 11;16:39-45. doi: 10.1016/j.ymgmr.2018.06.007. eCollection 2018 Sep.
- Background: PubMed 24222493Das AM, Goedecke K, Meyer U, Kanzelmeyer N, Koch S, Illsinger S, Lucke T, Hartmann H, Lange K, Lanfermann H, Hoy L, Ding XQ. Dietary habits and metabolic control in adolescents and young adults with phenylketonuria: self-imposed protein restriction may be harmful. JIMD Rep. 2014;13:149-58. doi: 10.1007/8904_2013_273. Epub 2013 Nov 13.
- Background: PubMed 30364670Ford S, O'Driscoll M, MacDonald A. Living with Phenylketonuria: Lessons from the PKU community. Mol Genet Metab Rep. 2018 Oct 18;17:57-63. doi: 10.1016/j.ymgmr.2018.10.002. eCollection 2018 Dec.
- Background: PubMed 31615158Green B, Browne R, Firman S, Hill M, Rahman Y, Kaalund Hansen K, Adam S, Skeath R, Hallam P, Herlihy I, Jenkinson F, Nicol C, Adams S, Gaff L, Donald S, Dawson C, Robertson L, Fitzachary C, Chan H, Slabbert A, Dunlop C, Cozens A, Newby C, Bittle V, Hubbard G, Stratton R. Nutritional and Metabolic Characteristics of UK Adult Phenylketonuria Patients with Varying Dietary Adherence. Nutrients. 2019 Oct 14;11(10):2459. doi: 10.3390/nu11102459.
- Background: PubMed 25005329Hansen KE, Ney D. A systematic review of bone mineral density and fractures in phenylketonuria. J Inherit Metab Dis. 2014 Nov;37(6):875-80. doi: 10.1007/s10545-014-9735-2. Epub 2014 Jul 9.
- Background: PubMed 29390507Hermida-Ameijeiras A, Crujeiras V, Roca I, Calvo C, Leis R, Couce ML. Arterial stiffness assessment in patients with phenylketonuria. Medicine (Baltimore). 2017 Dec;96(51):e9322. doi: 10.1097/MD.0000000000009322.
- Background: PubMed 20373144MacDonald A, Gokmen-Ozel H, van Rijn M, Burgard P. The reality of dietary compliance in the management of phenylketonuria. J Inherit Metab Dis. 2010 Dec;33(6):665-70. doi: 10.1007/s10545-010-9073-y. Epub 2010 Apr 7.
- Background: PubMed 19747868MacLeod EL, Gleason ST, van Calcar SC, Ney DM. Reassessment of phenylalanine tolerance in adults with phenylketonuria is needed as body mass changes. Mol Genet Metab. 2009 Dec;98(4):331-7. doi: 10.1016/j.ymgme.2009.07.016. Epub 2009 Aug 8.
- Background: PubMed 27595068Okano Y, Hattori T, Fujimoto H, Noi K, Okamoto M, Watanabe T, Watanabe R, Fujii R, Tamaoki T. Nutritional status of patients with phenylketonuria in Japan. Mol Genet Metab Rep. 2016 Aug 20;8:103-10. doi: 10.1016/j.ymgmr.2016.08.005. eCollection 2016 Sep.
- Individual participant dataSharing planned: No
Related trials for Phenylketonurias
RecruitingPhase 1
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
Phenylketonuria
RecruitingPhase 2
A Study of MZE782 in Adults With PKU
Phenylketonuria (PKU)
RecruitingPhase 3
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
Phenylketonuria
Recruiting
Impact of Phenylalanine Elevations on Brain and Cognition in Adult PKU Carriers
Carrier of Phenylketonuria, Healthy
RecruitingPhase 3
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
Phenylketonuria
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mojca Žerjav Tanšek, doctorate contact
Questions about this trial
What is this clinical trial studying?
A study testing Ultrasound of the jugular veins and addition of phenylalanine-free protein substitutes in people with Phenylketonurias and Nutritional and Metabolic Diseases, run by University Medical Centre Ljubljana.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Ajda Mezek, master (0038640656109, ajda.mezek@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
assess the differences between the group of patients with questionnaire (time frame: up to 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04969809, which also lists 21 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2021.